Small Interfering RNA (SIRNA) Therapeutics Market is expected to reach US$ 39.19 Bn. at a CAGR of 17.5 % during the forecast period (2024-2030).Small Interfering RNA (SIRNA) Therapeutics Market Overview:
Small Interfering RNAs, also called as silencing RNA, is a class of double stranded non-coding RNA molecules. These are the most widely used nucleic acid based sequence for interfering expression of specific genes. The siRNAs help to recognize unique pathways and to validate targets for various life threatening diseases such as cancer, AIDS etc.To Know About The Research Methodology :- Request Free Sample Report
Small Interfering RNA (SIRNA) Therapeutics Market Dynamics:
Higher efficiency of the siRNA compared to earlier reverse genetic technologies is considered to be the prime factor driving the market growth. siRNA has widespread applications; it is used to assess cellular phenotypes, including cytokinesis, apoptosis, insulin signalling and cell differentiation. The high potential of gene silencing of siRNA has resulted in many target-specific therapeutic applications for validating targets in cancer, HIV infection, hepatitis, etc. Rising number of clinical trials, short duration of pre-clinical development, rising government funding for research and developmental activities, well-established healthcare infrastructure are key drivers which augment the market growth. Additionally, as cancer remains a leading cause of global death, small interfering RNAs (siRBAs) emerge as significant advancements.They play a major role in regulating gene expression through a process known as RNA interference (RNAi), contributing favorably market expansion. The report highlights profiles of fifteen key players operating in various regions. It thoroughly examines market leaders, followers, and newcomers from a non-cooperating investor perspective in estimating the market size. The study focuses on regional influences on costs, the availability of advance technology, and specific researches and developements. Small Interfering RNA (siRNA) Therapeutics Market Segment Analysis: The global Small Interfering RNA (siRNA) therapeutics market is segmented on the basis of Type and Application. Since liposome-based systemic therapy is the most promising drug delivery method for in vivo siRNA delivery, it is expected to hold a dominant market share based on type. Liposomes are the first nano-drug delivery systems that have been successfully translated into real-time clinical applications. The second and third generations of liposomes have the ability to recognize specific receptors or enhance the liposome stabilities, which increase the use of liposome based delivery systems most commonly used in clinical applications. All these factors help in bolstering segment growth.Small Interfering RNA (siRNA) Therapeutics Market Regional Insights:
North America is expected to dominate the global market during the forecast period. A Rising number of clinical trials and new product launches in the region contribute to market growth. In addition to this, an increase in healthcare expenditure, government funding for research and development activities, well-established healthcare infrastructure create potential opportunities for the market growth in the region. APAC is expected to witness lucrative growth during the forecast period. The growth of the market in this particular region is driven by factors such as rising healthcare expenditure, favorable government reimbursement policies, and growing awareness of the range of therapists available to treat diseases like cancer, heart disease, and others. The report also helps in understanding the global Small Interfering RNA (siRNA) Therapeutics Market dynamics and structure by analyzing the market segments and project the Global market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the global market make the report investor’s an guide.Small Interfering RNA (siRNA) Therapeutics Market Report: Inquire before buying
Small Interfering RNA (siRNA) Therapeutics Market Report Coverage Details Base Year: 2023 Forecast Period: 2023-2030 Historical Data: 2019 to 2023 Market Size in 2023: US $ 12.67 Bn. Forecast Period 2024 to 2030 CAGR: 17.5% Market Size in 2029: US $ 39.19 Bn. Segments Covered: by Type Liposome Based Systemic Therapy Nanoparticle Based Systemic Therapy Other by Applications Hospital, Research Institutions Pharmaceutical and Biotechnology Companies Academic Institutions Other Small Interfering RNA (siRNA) Therapeutics Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Small Interfering RNA (siRNA) Therapeutics Key Players are:
1. GE Dharmacon 2. OPKO Health, Inc. 3. Alnylam Pharmaceuticals 4. Arrowhead Research Corp 5. Sanofi Genzyme 6. Genecon Biotechnologies Co., Ltd. 7. Arbutus Biopharma Corp 8. Silence Therapeutics AG 9. Sylentis S.A. 10. Olix Pharmaceuticals 11. GlaxoSmithKline 12. Isis Pharmaceuticals/ Ionis Pharmaceuticals 13. BenitecBiopharma Ltd. 14. Bio-Path Holdings Inc. 15. Calando PharmaceuticalsFrequently Asked Questions:
1. Which region has the largest share in Global Small Interfering RNA (siRNA) Therapeutics Market? Ans: North America region held the highest share in 2023. 2. What is the growth rate of Global Small Interfering RNA (siRNA) Therapeutics Market? Ans: The Global market is growing at a CAGR of 17.5% during forecasting period 2024-2030. 3. What is scope of the Global Small Interfering RNA (siRNA) Therapeutics Market report? Ans: Global market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Small Interfering RNA (siRNA) Therapeutics Market? Ans: The important key players in the Global market are – GE Dharmacon, OPKO Health, Inc., Alnylam Pharmaceuticals, Arrowhead Research Corp, Sanofi Genzyme, Genecon Biotechnologies Co., Ltd., Arbutus Biopharma Corp, Silence Therapeutics AG, Sylentis S.A., Olix Pharmaceuticals, GlaxoSmithKline, Isis Pharmaceuticals/ Ionis Pharmaceuticals, BenitecBiopharma Ltd., Bio-Path Holdings Inc., and Calando Pharmaceuticals 5. What is the study period of this Market? Ans: The Global market is studied from 2023 to 2030.
1. Small Interfering RNA (SiRNA) Therapeutics Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 1.4. Payload Carriers for siRNA Delivery 1.5. Patent Landscape for Payload Carriers 1.5.1. Lipid Nanoparticles (LNPs) 1.5.2. Virus-Like Particles (VLPs) 1.5.3. Polymeric Nano-Hydrogels 1.6. Examples of Patent Holders and Their Inventory for Small Interfering RNA (SiRNA) Therapeutics Industry 1.6.1. Alnylam 1.6.2. Other Dominant Patent Holders 1.7. Clinical Trial Data Summary 2. Small Interfering RNA (SiRNA) Therapeutics Market: Dynamics 2.1. Market Trends - Global 2.2. Market Dynamics - Global 2.2.1. Drivers 2.2.2. Restraints 2.2.3. Opportunities 2.2.4. Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technological Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Small Interfering RNA (SiRNA) Therapeutics Clinical Trial Analysis for Small Interfering RNA (SiRNA) Therapeutics 2.8. Key Opinion Leader Analysis for Small Interfering RNA (SiRNA) Therapeutics Industry 2.9. Analysis of Government Schemes and Initiatives for Small Interfering RNA (SiRNA) Therapeutics Industry 2.10. The Global Pandemic Impact on Small Interfering RNA (SiRNA) Therapeutics Market 3. Small Interfering RNA (SiRNA) Therapeutics Market: Global Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030) 3.1. Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 3.1.1. Liposome Based Systemic Therapy 3.1.2. Nanoparticle Based Systemic Therapy 3.1.3. Other 3.2. Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 3.2.1. Hospital, Research Institutions 3.2.2. Pharmaceutical and Biotechnology Companies 3.2.3. Academic Institutions 3.2.4. Other 3.3. Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Region (2023-2030) 3.3.1. North America 3.3.2. Europe 3.3.3. Asia Pacific 3.3.4. Middle East and Africa 3.3.5. South America 4. North America Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast (by Value in USD Million) (2023-2030) 4.1. North America Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 4.1.1. Liposome Based Systemic Therapy 4.1.2. Nanoparticle Based Systemic Therapy 4.1.3. Other 4.2. North America Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 4.2.1. Hospital, Research Institutions 4.2.2. Pharmaceutical and Biotechnology Companies 4.2.3. Academic Institutions 4.2.4. Other 4.3. North America Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Country (2023-2030) 4.3.1. United States 4.3.1.1. United States Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 4.3.1.1.1. Liposome Based Systemic Therapy 4.3.1.1.2. Nanoparticle Based Systemic Therapy 4.3.1.1.3. Other 4.3.1.2. United States Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 4.3.1.2.1. Hospital, Research Institutions 4.3.1.2.2. Pharmaceutical and Biotechnology Companies 4.3.1.2.3. Academic Institutions 4.3.1.2.4. Other 4.3.2. Canada 4.3.2.1. Canada Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 4.3.2.1.1. Liposome Based Systemic Therapy 4.3.2.1.2. Nanoparticle Based Systemic Therapy 4.3.2.1.3. Other 4.3.2.2. Canada Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 4.3.2.2.1. Hospital, Research Institutions 4.3.2.2.2. Pharmaceutical and Biotechnology Companies 4.3.2.2.3. Academic Institutions 4.3.2.2.4. Other 4.3.3. Mexico 4.3.3.1. Mexico Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 4.3.3.1.1. Liposome Based Systemic Therapy 4.3.3.1.2. Nanoparticle Based Systemic Therapy 4.3.3.1.3. Other 4.3.3.2. Mexico Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 4.3.3.2.1. Hospital, Research Institutions 4.3.3.2.2. Pharmaceutical and Biotechnology Companies 4.3.3.2.3. Academic Institutions 4.3.3.2.4. Other 5. Europe Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast (by Value in USD Million) (2023-2030) 5.1. Europe Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 5.2. Europe Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 5.3. Europe Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Country (2023-2030) 5.3.1. United Kingdom 5.3.1.1. United Kingdom Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 5.3.1.2. United Kingdom Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 5.3.2. France 5.3.2.1. France Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 5.3.2.2. France Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 5.3.3. Germany 5.3.3.1. Germany Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 5.3.3.2. Germany Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 5.3.4. Italy 5.3.4.1. Italy Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 5.3.4.2. Italy Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 5.3.5. Spain 5.3.5.1. Spain Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 5.3.5.2. Spain Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 5.3.6. Sweden 5.3.6.1. Sweden Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 5.3.6.2. Sweden Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 5.3.7. Austria 5.3.7.1. Austria Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 5.3.7.2. Austria Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 5.3.8. Rest of Europe 5.3.8.1. Rest of Europe Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 5.3.8.2. Rest of Europe Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 6. Asia Pacific Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast (by Value in USD Million) (2023-2030) 6.1. Asia Pacific Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 6.2. Asia Pacific Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 6.3. Asia Pacific Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Country (2023-2030) 6.3.1. China 6.3.1.1. China Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 6.3.1.2. China Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 6.3.2. S Korea 6.3.2.1. S Korea Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 6.3.2.2. S Korea Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 6.3.3. Japan 6.3.3.1. Japan Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 6.3.3.2. Japan Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 6.3.4. India 6.3.4.1. India Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 6.3.4.2. India Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 6.3.5. Australia 6.3.5.1. Australia Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 6.3.5.2. Australia Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 6.3.6. Indonesia 6.3.6.1. Indonesia Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 6.3.6.2. Indonesia Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 6.3.7. Malaysia 6.3.7.1. Malaysia Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 6.3.7.2. Malaysia Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 6.3.8. Vietnam 6.3.8.1. Vietnam Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 6.3.8.2. Vietnam Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 6.3.9. Taiwan 6.3.9.1. Taiwan Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 6.3.9.2. Taiwan Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 6.3.10. Rest of Asia Pacific 6.3.10.1. Rest of Asia Pacific Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 6.3.10.2. Rest of Asia Pacific Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 7. Middle East and Africa Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast (by Value in USD Million) (2023-2030) 7.1. Middle East and Africa Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 7.2. Middle East and Africa Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 7.3. Middle East and Africa Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Country (2023-2030) 7.3.1. South Africa 7.3.1.1. South Africa Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 7.3.1.2. South Africa Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 7.3.2. GCC 7.3.2.1. GCC Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 7.3.2.2. GCC Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 7.3.3. Nigeria 7.3.3.1. Nigeria Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 7.3.3.2. Nigeria Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 7.3.4. Rest of ME&A 7.3.4.1. Rest of ME&A Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 7.3.4.2. Rest of ME&A Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 8. South America Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast (by Value in USD Million) (2023-2030) 8.1. South America Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 8.2. South America Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 8.3. South America Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Country (2023-2030) 8.3.1. Brazil 8.3.1.1. Brazil Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 8.3.1.2. Brazil Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 8.3.2. Argentina 8.3.2.1. Argentina Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 8.3.2.2. Argentina Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 8.3.3. Rest Of South America 8.3.3.1. Rest Of South America Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Type (2023-2030) 8.3.3.2. Rest Of South America Small Interfering RNA (SiRNA) Therapeutics Market Size and Forecast, by Application (2023-2030) 9. Global Small Interfering RNA (SiRNA) Therapeutics Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Product Segment 9.3.3. End-user Segment 9.3.4. Revenue (2023) 9.3.5. Company Locations 9.4. Leading Small Interfering RNA (SiRNA) Therapeutics Market Companies, By Market Capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 11. 10.1 Horizon Discovery Ltd. 11.1.1. Company Overview 11.1.2. Business Portfolio 11.1.3. Financial Overview 11.1.4. SWOT Analysis 11.1.5. Strategic Analysis 11.1.6. Recent Developments 10.2 OPKO Health, Inc. 10.3 Alnylam Pharmaceuticals 10.4 Arrowhead Research Corp 10.5 Sanofi Genzyme 10.6 Biomics Biopharma 10.7 Arbutus Biopharma Corp 10.8 Silence Therapeutics AG 10.9 Sylentis S.A. 10.10 Olix Pharmaceuticals 10.11 GlaxoSmithKline 10.12 Isis Pharmaceuticals/ Ionis Pharmaceuticals 10.13 BenitecBiopharma Ltd. 10.14 Bio-Path Holdings Inc. 12. Key Findings 13. Industry Recommendations 14. Small Interfering RNA (SiRNA) Therapeutics Market: Research Methodology